Abstract
The world is facing an increase in the cancer incidence and mortality, making malignant neoplasms one of the leading causes of death worldwide. This increasing trend is predicted to continue in the next decades, with an estimated >23 million new cases and 13 million deaths caused by cancer by 2030. Excluding non-melanoma skin cancer, lung, breast, colorectal, prostate, and stomach cancers are the most common, while lung, liver, stomach, colorectal, breast, and esophageal cancers have the highest mortality rate. The prevalence of cancer in developed countries is >two-fold that in developing countries, however, cancer rates are expected to rise among developing countries, because of the ageing, population growth, and the adoption of unhealthy western lifestyle habits. Delivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers. The global cost of cancer in 2008 due to premature death and disability, excluding direct medical costs, was estimated at $895 billion in the United States. Measures to reduce the incidence of cancer include the avoidance and modification of risk factors, vaccination against oncogenic biologic agents and the early detection of risk lesions through screening programs.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bloom DE, Cafiero ET, Jané-Lloppis E et al (2011) The global economic burden of noncommunicable diseases. World Economic Forum, Geneva
Marrero SL, Bloom DE, Adashi EY (2012) Noncommunicable diseases: a global health crisis in a new world order. JAMA 307:2037–2038. https://doi.org/10.1001/jama.2012.3546
World Health Organization Publication (2014) Global status report on noncommunicable diseases. http://www.who.int/nmh/publications/ncd-status-report-2014/en/. Accessed 2 Mar 2015
Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254
American Cancer Society (2015). Global cancer facts & figures, 3rd edn. http://www.cancer.org/research/cancerfactsstatistics/global. Accessed 2 Mar 2015
Steart BW, Wild CP (2014) World cancer report 2014. International Agency for Research on Cancer, Lyon
Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of disease Study 2010. Lancet 380:2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2
Murray CJ, Vos T, Lozano R et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197–2223. https://doi.org/10.1016/S0140-6736(12)61689-4
National Cancer Institute (2012) Cancer trends progress report – 2011/2012 Update Bethesda, U.S.A. http://progressreport.cancer.gov. Accessed 2 Mar 2015
Curado MP, Edwards B, Shin HR et al (2007) Cancer incidence in five continents, International Agency for Research on Cancer Scientific Publications, no 160, vol IX. IARC, Lyon
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386. https://doi.org/10.1002/ijc.29210
Bray F, Jemal A, Grey N, Ferlay J, Forman D (2012) Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 13:790–780. https://doi.org/10.1016/S1470-2045(12)70211-5
Beaglehole R, Bonita R, Magnusson R (2011) Global cancer prevention: an important pathway to global health and development. Public Health 125:821–831. https://doi.org/10.1016/j.puhe.2011.09.029
Soerjomataram I, Lortet-Tieulent J, Parkin DM et al (2012) Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet 380:1840–1850. https://doi.org/10.1016/S0140-6736(12)60919-2
John R, Ross H (2010) Economic value of disability adjusted life years lost to cancers: 2008. J Clin Oncol 28:1561
John R, Ross H (2010) The global economic cost of cancer. American Cancer Society and the LIVESTRONG Organization. http://www.cancer.org/AboutUs/GlobalHealth/global-economic-costs-of-cancer-report-pdf. Accessed 2 Mar 2015
Guy GP Jr, Ekwuemw DU, Yabroff KR et al (2013) Economic burden of cancer survivorship among adults in the United States. J Clin Oncol 31:3749–3757. https://doi.org/10.1200/JCO.2013.49.1241
Yabroff KR, Lund J, Kepka D et al (2011) Economic burden of cancer in the US: estimates, projections, and future research. Cancer Epidemiol Biomark Prev 20:2006–2014. https://doi.org/10.1158/1055-9965.EPI-11-0650
Luengo-Fernandez R, Leal J, Gray A et al (2013) Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 14:1165–1174. https://doi.org/10.1016/S1470-2045(13)70442-X
Ott JJ, Ullrich A, Mascarenhas M et al (2010) Global cancer incidence and mortality caused by behavior and infection. J Public Health (Oxf) 33:223–233. https://doi.org/10.1093/pubmed/fdq076
Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomark Prev 19:1893–1907. https://doi.org/10.1158/1055-9965.EPI-10-0437
World Health Organization Publication (2013) WHO report on the global tobacco epidemic. http://www.who.int/tobacco/global_report/2013/en/. Accessed 2 Mar 2015
International Agency for Research on Cancer (2012) A review of human carcinogens: personal habits and indoor combustions, IARC Monographs on the evaluation of carcinogenic risks to humans, vol 100E. International Agency for Research on Cancer, Lyon, pp 379–384
World Health Organization Publication (2014) Global status report on alcohol and health. http://www.who.int/substance_abuse/publications/global_alcohol_report/en/. Accessed 02 Mar 2015
World Cancer Research Fund & American Institute for Cancer Research (2007) Food, nutrition, physycal activity, and the prevention of cancer: a global perpective. Second expert report, pp 280–288
De Martel C, Ferlay J, Franceschi S et al (2012) Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13:607–615. https://doi.org/10.1016/S1470-2045(12)70137-7
Aberle DR, Adams AM, Berg CD et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365:395–409. https://doi.org/10.1056/NEJMoa1102873
Agency for Healthcare Research and Quality (2014) The guide to clinical preventive services 2014: recommendations of the U.S. Preventive Services Task Force. http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/guide/index.html. Accessed 2 Mar 2015
Christensen JD, Tong BC (2013) Computed tomography screening for lung cancer: where are we now. N C Med J 74:406–410
World Health Organization Publication (2014) WHO position paper on mammography screening. http://www.who.int/cancer/publications/mammography_screening/en/. Accessed 2 Mar 2015
Doubeni CA (2014) The impact of colorectal cancer screening on the US population: is time to celebrate. Cancer 120:2810–2813. https://doi.org/10.1002/cncr.28789
Patnick J, Segnan N, Von Karsa L et al (2010) European guidelines for quality assurance in colorectal cancer screening and diagnosis. http://bookshop.europa.eu/is-bin/INTERSHOP.enfinity/WFS/EU-Bookshop-Site/en_GB/-/EUR/ViewPublication-Start?PublicationKey=ND3210390. Accessed 2 Mar 2015
Burt RW (2000) Colon cancer screening. Gastroenterology 119:837–853
Schröder FH, Hugosson J, Roobol MJ et al (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027–2035
Andriole GL, Crawford ED, Grubb RL et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310–1319. https://doi.org/10.1056/NEJMoa0810696
National Cancer Institute (2015) Cervical cancer screening PDQ®. http://www.cancer.gov/cancertopics/pdq/screening/cervical/HealthProfessional/page1. Accessed 2 Mar 2015
World Health Organization Publication (2014) Comprehensive cervical cancer control: a guide to essential practice. http://www.who.int/reproductivehealth/publications/cancers/cervical-cancer-guide/en/. Accessed 2 Mar 2015
Patterson SL, Maresso KC, Hawk E (2013) Cancer chemoprevention: successes and failures. Clin Chem 59:94–101. https://doi.org/10.1373/clinchem.2012.185389
Steward WP, Beown K (2013) Cancer chemoprevention: a rapidly evolving field. Br J Cancer 109:1–7. https://doi.org/10.1038/bjc.2013.280
Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282
Vogel VG, Constantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727–2741
Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomized placebo-controlled trial. Lancet 383:1041–1048. https://doi.org/10.1016/S0140-6736(13)62292-8
Ruder EH, Laiyemo AO, Graubard BI et al (2011) Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 106:1340–1350. https://doi.org/10.1038/ajg.2011.38
Rothwell PM, Wilson M, Elwin CE et al (2010) Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 376:1741–1750. https://doi.org/10.1016/S0140-6736(10)61543-7
Cuzick J, Thorat MA, Andriole G et al (2014) Prevention and early detection of prostate cancer. Lancet Oncol 15:e484–e492. https://doi.org/10.1016/S1470-2045(14)70211-6
Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202. https://doi.org/10.1056/NEJMoa0908127
Weintraub K (2014) Vaccines: taking a shot at protection. Nature 516:S12–S13. https://doi.org/10.1038/516S12a
World Health Organization Publication (2010) Hepatitis B vaccines: WHO position paper – recommendations. Vaccine 28:589–590. https://doi.org/10.1016/j.vaccine.2009.10.110
Markowitz LE, Tsu V, Deeks SL et al (2012) Human papillomavirus vaccine introduction: the first five years. Vaccine 30:F139–F148. https://doi.org/10.1016/j.vaccine.2012.05.039
Dochez C, Bogers JJ, Verhelst R et al (2014) HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 32:1595–1601. https://doi.org/10.1016/j.vaccine.2013.10.081
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stock, G.T., Aguiar, P.N., Tadokoro, H., De Mello, R.A. (2019). Cancer Epidemiology and Screening. In: De Mello, R., Mountzios, G., Tavares, Á. (eds) International Manual of Oncology Practice. Springer, Cham. https://doi.org/10.1007/978-3-030-16245-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-16245-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-16244-3
Online ISBN: 978-3-030-16245-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)